Crino L.; Bidoli P.; Delmonte A.; Grossi F.; De Marinis F.; Ardizzoni A.; Vitiello F.; Lo Russo G.; Parra H.S.; Cortesi E.; Cappuzzo F.; Calabro L.; Tiseo M.; Turci D.; Gamucci T.; Antonelli P.; Morabito A.; Chella A.; Giannarelli D.; Galetta D., Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population, «THE ONCOLOGIST», 2019, 24, pp. e1165 - e1171 [Scientific article]
Cinausero M.; Laprovitera N.; Maglio G.D.; Gerratana L.; Riefolo M.; Macerelli M.; Fiorentino M.; Porcellini E.; Buoro V.; Gelsomino F.; Squadrilli A.; Fasola G.; Negrini M.; Tiseo M.; Ferracin M.; Ardizzoni A., KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC, «THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY», 2019, 11, Article number: 1758835919885540 , pp. 1 - 13 [Scientific article]Open Access
Rihawi, Karim; Alfieri, Roberta; Fiorentino, Michelangelo; Fontana, Francesca; Capizzi, Elisa; Cavazzoni, Andrea; Terracciano, Mario; La Monica, Silvia; Ferrarini, Alberto; Buson, Genny; Petronini, Pier Giorgio; Ardizzoni, Andrea, MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report, «TRANSLATIONAL ONCOLOGY», 2019, 12, pp. 116 - 121 [Scientific article]Open Access
Di Nunno V, Mollica V, Santoni M, Gatto L, Schiavina R, Fiorentino M, Brunocilla E, Ardizzoni A, Massari F, New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes., «CLINICAL GENITOURINARY CANCER», 2019, 1, pp. E871 - E877 [Scientific article]
Di Nunno, Vincenzo; Mollica, Veronica; Santoni, Matteo; Gatto, Lidia; Schiavina, Riccardo; Fiorentino, Michelangelo; Brunocilla, Eugenio; Ardizzoni, Andrea; Massari, Francesco, New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes, «CLINICAL GENITOURINARY CANCER», 2019, 17, pp. 871 - 877 [Scientific article]
Raschi E, Antonazzo IC, La Placa M, Ardizzoni A, Poluzzi E, De Ponti F., Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System., «THE ONCOLOGIST», 2019, 24, pp. e1228 - e1231 [Scientific article]
Mazzaschi, Giulia; Facchinetti, Francesco; Missale, Gabriele; Canetti, Diana; Madeddu, Denise; Zecca, Alessandra; Veneziani, Michele; Gelsomino, Francesco; Goldoni, Matteo; Buti, Sebastiano; Bordi, Paola; Aversa, Franco; Ardizzoni, Andrea; Quaini, Federico; Tiseo, Marcello, The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC, «LUNG CANCER», 2019, 127, pp. 153 - 163 [Scientific article]
Gelsomino, Francesco; Lamberti, Giuseppe; Parisi, Claudia; Casolari, Laura; Melotti, Barbara; Sperandi, Francesca; Ardizzoni, Andrea, The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers, «CANCER TREATMENT REVIEWS», 2019, 79, Article number: 101887 , pp. 1 - 11 [Scientific article]
Mollica V, Di Nunno V, Corcioni B, Fiorentino M, Nobili E, Schiavina R, Golfieri R, Brunocilla E, Ardizzoni A, Massari F, A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor., «ANTI-CANCER DRUGS», 2018, 29, pp. 911 - 913 [Scientific article]
Gelsomino, Francesco*; Vitale, Giovanni; Ardizzoni, Andrea, A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event, «INVESTIGATIONAL NEW DRUGS», 2018, 36, pp. 144 - 146 [Scientific article]
Gelfo V, Mazzeschi M, Grilli G, Lindzen Moshit, Santi Spartaco, D'Uva G, Győrffy B, Ardizzoni A, Yarden Y, Lauriola M., A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy, «CANCERS», 2018, 10, pp. 355 - 370 [Scientific article]
Ferrarini A, Forcato C, Buson G, Tononi P, Del Monaco V, Terracciano M, Bolognesi C, Fontana F, Medoro G, Neves R, Möhlendick B, Rihawi K, Ardizzoni A, Sumanasuriya S, Flohr P, Lambros M, de Bono J, Stoecklein NH, Manaresi N, A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products., «PLOS ONE», 2018, 1, Article number: e0193689 , pp. 1 - 24 [Scientific article]Open Access
Morgensztern, Daniel*; Cobo, Manuel; Ponce Aix, Santiago; Postmus, Pieter E.; Lewanski, Conrad R.; Bennouna, Jaafar; Fischer, Jürgen R.; Juan-Vidal, Oscar; Stewart, David J.; Fasola, Gianpiero; Ardizzoni, Andrea; Bhore, Rafia; Wolfsteiner, Marianne; Talbot, Denis C.; Jin Ong, Teng; Govindan, Ramaswamy, ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC), «CANCER», 2018, 124, pp. 4667 - 4675 [Scientific article]
Dall'Olio, Filippo Gustavo; Sperandi, Francesca; Rihawi, Karim; Gargiulo, Mauro; Melotti, Barbara; Brocchi, Stefano; Gelsomino, Francesco*; Ardizzoni, Andrea, Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding, «JOURNAL OF THORACIC ONCOLOGY», 2018, 13, pp. e247 - e248 [Scientific article]
Goss GD, Felip E , Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Guclu S, Isla D, Min YJ, Morabito A, Ardizzoni A, Gadgeel SM, Fülöp A, Bühnemann C, Gibson N, Krämer N, Solca F, Cseh A, Ehrnrooth E, Soria JC., Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial., «JAMA ONCOLOGY», 2018, 4, pp. 1189 - 1197 [Scientific article]
